StockMarketWire.com - Clinical stage drug development company Evgen Pharma said preclinical data had showed its lead cancer drug candidate SFX-01 was an inhibitor of SHP2, a protein associated with a number of different cancer types.






At 8:10am: [LON:EVG] Evgen Pharma Plc share price was 0p at 8.3p



Story provided by StockMarketWire.com